066700.Kq
The company operates in the pharmaceuticals industry, generating revenue primarily through the development, production, and sale of prescription drugs and related healthcare products.
Business. The company operates in the pharmaceuticals industry, generating revenue primarily through the development, production, and sale of prescription drugs and related healthcare products.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
The company operates in the pharmaceuticals industry, generating revenue primarily through the development, production, and sale of prescription drugs and related healthcare products.
The company maintains a relatively strong liquidity position, with a current ratio of 1.95, indicating that it has sufficient current assets to cover its current liabilities. However, the liquidity risk is assessed as medium, and the company has a net cash position that is negative after subtracting total debt, suggesting potential pressure on its short-term liquidity. The company's debt-to-equity ratio is 0.3, which is relatively low, indicating a conservative capital structure.
In terms of profitability, the company's return on equity (ROE) is 7.63%, and its return on assets (ROA) is 4.11%. These figures suggest that the company is generating a moderate return on its equity and assets, which is in line with the industry's preferred metrics. The company's operating margin, calculated as operating income divided by revenue, is 3.74%, which is a key indicator of its operational efficiency.
The company's revenue is concentrated in a single business segment, as disclosed in its financial statements, with no significant geographic diversification reported. This concentration may expose the company to higher risk if the segment or region experiences a downturn. The company's capital expenditures are negative, indicating that it is generating more cash from operations than it is spending on capital investments.
The company's growth trajectory is expected to remain stable, with no significant changes in revenue or earnings projected for the next fiscal year. The company's free cash flow is positive, at 15.55 billion KRW, which provides flexibility for reinvestment or shareholder returns. The company's risk assessment indicates a low potential for dilution, with no immediate pressure from share issuance or other dilutive events.
Recent events, as disclosed in the company's filings, include no material changes in its business operations or financial position. The company has not issued any new shares or taken on additional debt in the recent period, maintaining a stable capital structure. The company's financial performance is consistent with its historical trends, with no significant deviations in revenue or profitability.
- The company has a conservative capital structure with a low debt-to-equity ratio of 0.3.
- The company's liquidity position is moderate, with a current ratio of 1.95 but a negative net cash position after debt.
- The company's profitability is moderate, with a return on equity of 7.63% and a return on assets of 4.11%.
- The company's revenue is concentrated in a single business segment, which may increase its exposure to market risks.
- The company's free cash flow is positive, providing flexibility for reinvestment or shareholder returns.
- The company has a low potential for dilution, with no immediate pressure from share issuance or other dilutive events.
Bull / Bear case
analysis pipelineIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- Net cash is negative after subtracting total debt.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Capex To Revenuecapital_expenditure / revenue
- Return On Equitynet_income / total_equity
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Cash Conversion Ratiooperating_cash_flow / net_income
- 066700.KQ Market data — financials · 2026-05-26